Roundtable Forum: How Was the COVID-19 Vaccine Developed So Quickly? Insights into Accelerated Vaccine Development
Currently, the risk of the COVID-19 epidemic in China is gradually decreasing, but the global epidemic risk continues to intensify. The shift of the epidemic’s epicenter from China to Western Europe, then to the United States, and subsequently to South America underscores the persistent pandemic nature of COVID-19. Ultimately, vaccination remains the only means to control the spread and prevalence of the epidemic.
The global outbreak of COVID-19 has brought unprecedented public attention to vaccines. Issues such as vaccine development timelines, technological pathways, and reliability have transcended professional circles to become matters of widespread public concern. In response, the Chinese Health Law Society, the Medical Laboratory Industry Branch of the China Health Industry Enterprise Management Association, BGI Win-Win, and VCBeat have jointly initiated this online roundtable forum. The discussion aims to analyze the progress, advantages, and disadvantages of different R&D approaches for COVID-19 vaccines, thereby sparking a broader conversation on emerging biotechnological pathways.
Event Time: June 10, 2020 (Wednesday) 20:00
Special Guests: Dr. Huang Wenlin, Dr. Zhang Xiaoning, Dr. Yang Naibo, Dr. Li Linxian
Meanwhile, we invite the audience to raise questions of interest and actively participate in the roundtable discussion.
Scan the QR code to enter the live streaming room
Event Topics:
1. Global R&D and Progress of COVID-19 Vaccines Across Different Technological Platforms
2. Progress in the Development of COVID-19 Vaccines in China and the Corresponding Development of Different Companies
3. Discussion on the Origin and Development Prospects of New Technological Pathways in Vaccine R&D (e.g., RNA)
On the Joint International Action Against COVID-19
To effectively address practical challenges and support global solidarity in the fight against the pandemic, the Chinese Society for Health Law, the China Disabled Persons’ Welfare Foundation, the Chinese-Foreign Entrepreneurs Association, the Shanghai Dongfang Medical Innovation Research Institute, and the Medical Laboratory Industry Branch of the China National Health Industry Enterprise Management Association, together with Debao Hengsheng Medical, BGI Win-Win Fund, and Sinopharm Health (Shanghai) Industrial Co., Ltd., have jointly launched the “Joint International Action Against COVID-19.” This initiative leverages the credibility, influence, and organizational capacity of industry associations to strongly consolidate professional expertise within the sector, meticulously build a diversified platform for cooperation and exchange, and harness the advantages of industry organizations to stand with people worldwide in overcoming these difficult times.
